Molecular Imaging, Inc initiates search for Director, Oncology pharmaco-IMAGING

October 2, 2013
Molecular Imaging, Inc., (MII) a specialty contract research organization providing multi-modality preclinical in vivo imaging services to pharmaceutical and biotechnology companies, today announced it has initiated a global search to fill a newly created role: Director, Oncology pharmaco-IMAGING.

The new position is aimed at building on an existing successful business to intensify focus on oncology discovery pharmacology, for development of new pharmaceutical company relationships.  “A highly consultative, collaborative scientific approach is the foundation for our services”, stated Dr. Patrick McConville, Co-founder and CSO. “This new position is aimed directly at even greater focus on that concept.” he added

The search will identify a Ph.D. level oncology discovery expert with 10+ years’ experience, to become part of its scientific team reporting to the CSO. The incumbent will work directly with pharma company executives and investigators to enhance their discovery efforts through research outsourcing. The new Director will collaborate with MII Imaging Scientists to develop compelling in vivo solutions for oncology drug discovery and translational science. This exciting new role will expose the incumbent to the entire spectrum of oncology discovery effort, including the full diversity of related models and technologies, and companies involved in the effort.

“Our company has become recognized for enhancing discovery and translational programs for clients though expert integration of in vivo imaging”, stated Dr. McConville. “In recognition of the critical importance of understanding the underlying molecular target and related pharmacology to ensure imaging maximally benefits an oncology drug program, we are adding this key position. The incumbent will take on new responsibilities for developing new long term research programs and collaborations with pharmaceutical companies, and will participate in developing oncology scientific strategy and subsequent services expansion,” he added.

Dr. Dick Leopold, Co-founder and VP, Oncology commented: “Expert knowledge of oncology discovery, molecular targets and all aspects of pharmacology is absolutely essential as a quality service provider.  It’s been extremely pleasing to see the diversity of ways we have added benefit to discovery efforts through imaging. Having been in the shoes of our clients has been instrumental to our successes, and I’m greatly looking forward to the positive impact the new role will have in demonstrating the benefits of pharmaco-IMAGING for new clients.”

The company is looking to fill the position quickly and is reviewing early applications. The position will provide a highly attractive and competitive package.  Interested applicants are invited to review the detailed Job Description and apply.

About Molecular Imaging, Inc.
Molecular Imaging, Inc. is a specialty contract research organization (CRO) located in Ann Arbor, Michigan. The company enhances discovery and translational research through in vivo pharmaco-IMAGING designed to interrogate target biology and pharmacology. Molecular Imaging employs a wide array of relevant small animal models, traditional technologies and imaging technologies, including MRI, micro-CT, micro-PET, SPECT and optical (bioluminescence and molecular fluorescence tomography) to quantitatively measure response to therapy at anatomical, functional and molecular levels.